<DOC>
	<DOCNO>NCT01719536</DOCNO>
	<brief_summary>The purpose study compare icotinib induction maintenance chemotherapy first-line treatment advance non-small cell lung cancer ( NSCLC ) patient EGFR mutation .</brief_summary>
	<brief_title>Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment EGFR Positive Lung Adenocarcinoma Patients</brief_title>
	<detailed_description>This study design evaluate efficacy safety icotinib pemetrexed-based first-line induction maintenance chemotherapy advance lung adenocarcinoma EGFR-mutation，primary endpoint progress-free survival，second endpoint include overall survival , time progression , .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Recurrent progressive NonSmall Cell Lung Cancer stage IV IIIB patient . Positive EGFR Mutation . No previous systemic anticancer therapy . Measurable lesion accord RECIST least one measurable lesion previously irradiate , unless disease progression document site . Provision write informed consent . Experience AntiEGFR ( epidermal growth factor receptor ) Monoclonal Antibody small molecular compound therapy gefitinib , erlotinib Cetuximab . Evidence clinically active Interstitial Lung Diseases ( Patients chronic , stable , radiographic change asymptomatic need exclude ) . Known severe hypersensitivity icotinib excipients product . Evidence significant clinical disorder laboratory find make undesirable subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>